Programs

To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Multi-site Efficacy and Safety Trial of Intrapartum Azithromycin in Low- and Middle-Income Countries

This study will test whether an antibiotic taken during labor can prevent infections in mothers and newborns in seven low- and middle-income countries. It will be conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) through their Global Network for Women’s and Children’s Health Research (Global Network) in partnership with the Bill & Melinda Gates Foundation.

Summit Virtual Series: 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers

To address the growing need for evidence that improves the type and quality of care and support provided to persons with dementia and their caregivers, the National Institute on Aging (NIA) is hosting the Summit Virtual Meeting Series: 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers. The Virtual Summit Series will build on the foundation laid by the 2017 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers. This series aims to expand upon what was learned in the previous summit and spark new innovative ideas from those living with dementia, caregivers, researchers, providers, and advocates

NINDS Healthcare Disparities in Tribal Communities Summer Internship Program

The NINDS Healthcare Disparities in Tribal Communities (HDTC) Summer Internship Program (SIP) is a student research training program in brain and nervous system research. The program focuses on neurological disorders and healthcare disparities and seeks to provide research experiences and career development opportunities for Native American students, along with students from other underrepresented communities.

Biomarkers Consortium - Mucosal Healing in UC: Definition, Treatment Target and Clinical Endpoints

This project will establish a common methodology for a histologic measurement of a mucosal healing endpoint for treatment of UC that demonstrates clear prognostic value for long-term outcomes for patients that the scientific community can utilize when developing therapeutics for UC.

11th International Forum on Rheumatoid Arthritis (IFRA)

The 11th International Forum on Rheumatoid Arthritis: Pathogenesis and Emerging Therapeutic Strategies (IFRA 2019) is designed to bring together leading rheumatologists from Europe, the United States and Asian countries working to better understand the pathogenesis and emerging therapeutic strategies in rheumatoid arthritis (RA).

Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED)

The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systemic Lupus Erythematosus & Related Autoimmune Disorders

Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus & Related Autoimmune Disorders is an initiative of the Accelerating Medicines Partnership (AMP), which is a multi-sector, pre-competitive  partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases.

Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)

The NIMBLE Project is a comprehensive, five-year collaborative effort to standardize, compare and appropriately validate imaging and circulating biomarkers for NASH to: 1. Diagnose and stage the disease and; 2. Measure response to therapeutic intervention.

Biomarkers Consortium - Workshop: Defining an Evidentiary Criteria Framework for Surrogate Endpoint Qualification

The FNIH Biomarkers Consortium and FDA hosted a workshop to provide a Framework for Defining the Evidentiary Criteria for Surrogate Endpoint Qualification on July 30-31, 2018. The workshop aimed to create alignment of the biomedical community and regulators on the levels of evidence required to qualify biomarkers for use in drug development, with an emphasis on surrogate endpoints and specific clinical outcome measures.

Biomarkers Consortium - Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders

This project will aim to standardize and validate measurement methods for inflammatory markers associated with Alzheimer’s Disease and/or Major Depressive Disorder to ultimately identify a unique biosignature of disease. The identified biosignature would greatly assist with medication development, patient diagnosing, and patient selection for clinical trials.